Assessing recovery rates in patients with secondary hypothyroidism
Rate of Recovery of Secondary Hypothyroidism in Patients With Pituitary Disorders.
This study is testing how well patients with pituitary disorders recover from secondary hypothyroidism after gradually reducing their thyroid medication.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax) |
| Trial ID | NCT05276856 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the recovery rate of secondary hypothyroidism in patients with pituitary disorders. It will involve three stages, starting with the identification and enrollment of approximately 90-100 patients from a database, followed by a stepwise T4 withdrawal protocol to assess their response to reduced T4 therapy. Laboratory samples will be collected to confirm adequate hormone replacement before and during the study.
Who should consider this trial
Good fit: Ideal candidates include individuals with a confirmed diagnosis of secondary hypothyroidism who are currently on T4 replacement therapy.
Not a fit: Patients with uncontrolled cardiovascular disease, congestive heart failure, or mental health disorders, as well as those not adequately replaced with low T4 levels, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the recovery potential of patients with secondary hypothyroidism, potentially leading to improved management strategies.
How similar studies have performed: While this approach is observational and may have been explored in various forms, the specific methodology of T4 withdrawal in secondary hypothyroidism is less commonly tested, making this study somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of secondary hypothyroidism who are currently taking T4 replacement therapy Exclusion Criteria: * uncontrolled cardiovascular disease * uncontrolled congestive heart failure * uncontrolled mental health disorder * not adequately replaced and have low T4 level.
Where this trial is running
Halifax
- Nova Scotia Health — Halifax, Canada (Recruiting)
Study contacts
- Study coordinator: Hazem Aljumah
- Email: haaljumah1@gmail.com
- Phone: +17822340095
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.